To be screened for eligibility

To participate in the clinical trial

References

Print PDF

 

  1. Silk, A.W. and O.J. Finn, Cancer vaccines: a promising cancer therapy against all odds. Future Oncol, 2007. 3(3): p. 299-306.
  2. Nagorsen, D. and E. Thiel, Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin Cancer Res, 2006. 12(10): p. 3064-9.
  3. Rosenberg, S.A., J.C. Yang, and N.P. Restifo, Cancer immunotherapy: moving beyond current vaccines. Nat Med, 2004. 10(9): p. 909-15.
  4. Rivoltini, L., et al., Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control? Expert Opin Biol Ther, 2005. 5(4): p. 463-76.
  5. Demanet, C., et al., Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack? Blood, 2004. 103(8): p. 3122-30.
  6. Filaci, G. and N. Suciu-Foca, CD8+ T suppressor cells are back to the game: are they players in autoimmunity? Autoimmun Rev, 2002. 1(5): p. 279-83.
  7. Jonuleit, H. and E. Schmitt, The regulatory T cell family: distinct subsets and their interrelations. J Immunol, 2003. 171(12): p. 6323-7.
  8. Ben-Baruch, A., Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol, 2006. 16(1): p. 38-52.
  9. Elliott, R.L. and G.C. Blobe, Role of transforming growth factor Beta in human cancer. J Clin Oncol, 2005. 23(9): p. 2078-93.
  10. Liu, V.C., et al., Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol, 2007. 178(5): p. 2883-92.
  11. Zhou, J., et al., The expression of interleukin-10 in patients with primary ovarian epithelial carcinoma and in ovarian carcinoma cell lines. J Int Med Res, 2007. 35(3): p. 290-300.
  12. Zou, W., Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer, 2005. 5(4): p. 263-74.
  13. Zhang, X., et al., CD4-8- dendritic cells prime CD4+ T regulatory 1 cells to suppress antitumor immunity. J Immunol, 2005. 175(5): p. 2931-7.
  14. Terabe, M., et al., Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med, 2003. 198(11): p. 1741-52.
  15. Nefedova, Y., et al., Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol, 2004. 172(1): p. 464-74.
  16. Prud'homme, G.J. and C.A. Piccirillo, The inhibitory effects of transforming growth factor-beta-1 (TGF-beta1) in autoimmune diseases. J Autoimmun, 2000. 14(1): p. 23-42.
  17. Pakravan, N., A.T. Hassan, and Z.M. Hassan, Naturally Occurring Self-Reactive CD4(+)CD25(+) Regulatory T Cells: Universal Immune Code. Cell Mol Immunol, 2007. 4(3): p. 197-201.
  18. Sacher, T., et al., CpG-ODN-induced inflammation is sufficient to cause T-cell-mediated autoaggression against hepatocytes. Eur J Immunol, 2002. 32(12): p. 3628-37.
  19. Ganss, R., et al., Autoaggression and tumor rejection: it takes more than self-specific T-cell activation. Immunol Rev, 1999. 169: p. 263-72.
  20. Mosmann, T.R. and S. Sad, The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today, 1996. 17(3): p. 138-46.
  21. Bashyam, H., Th1/Th2 cross-regulation and the discovery of IL-10. J Exp Med, 2007. 204(2): p. 237.
  22. Nishimura, T., et al., The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother Pharmacol, 2000. 46 Suppl: p. S52-61.
  23. Chamoto, K., et al., Critical role of the Th1/Tc1 circuit for the generation of tumor-specific CTL during tumor eradication in vivo by Th1-cell therapy. Cancer Sci, 2003. 94(10): p. 924-8.
  24. Winter, H., et al., Tumour-induced polarization of tumour vaccine-draining lymph node T cells to a type 1 cytokine profile predicts inherent strong immunogenicity of the tumour and correlates with therapeutic efficacy in adoptive transfer studies. Immunology, 2003. 108(3): p. 409-19.
  25. Stremmel, C., et al., B7-2 expressed on EL4 lymphoma suppresses antitumor immunity by an interleukin 4-dependent mechanism. J Exp Med, 1999. 189(6): p. 919-30.
  26. Nakamura, T., et al., Roles of IL-4 and IFN-gamma in stabilizing the T helper cell type 1 and 2 phenotype. J Immunol, 1997. 158(6): p. 2648-53.
  27. Matzinger, P., Tolerance, danger, and the extended family. Annu Rev Immunol, 1994. 12: p. 991-1045.
  28. Janeway, C.A., Jr., The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today, 1992. 13(1): p. 11-6.
  29. Banchereau, J. and R.M. Steinman, Dendritic cells and the control of immunity. Nature, 1998. 392(6673): p. 245-52.
  30. Reis e Sousa, C., Dendritic cells as sensors of infection. Immunity, 2001. 14(5): p. 495-8.
  31. Horwitz, D.A., S.G. Zheng, and J.D. Gray, The role of the combination of IL-2 and TGF-beta or IL-10 in the generation and function of CD4+ CD25+ and CD8+ regulatory T cell subsets. J Leukoc Biol, 2003. 74(4): p. 471-8.
  32. Bodmer, S., et al., Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J Immunol, 1989. 143(10): p. 3222-9.
  33. Trapani, J.A., The dual adverse effects of TGF-beta secretion on tumor progression. Cancer Cell, 2005. 8(5): p. 349-50.
  34. Munn, D.H., et al., Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med, 1999. 189(9): p. 1363-72.
  35. Bobe, P., et al., Nitric oxide mediation of active immunosuppression associated with graft-versus-host reaction. Blood, 1999. 94(3): p. 1028-37.
  36. Rayman, P., et al., Effect of renal cell carcinomas on the development of type 1 T-cell responses. Clin Cancer Res, 2004. 10(18 Pt 2): p. 6360S-6S.
  37. Sparano, A., et al., Modulation of Th1 and Th2 cytokine profiles and their association with advanced head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg, 2004. 131(5): p. 573-6.
  38. Baier, P.K., et al., Cytokine expression in colon carcinoma. Anticancer Res, 2005. 25(3B): p. 2135-9.
  39. Kumar, R., et al., Th1/Th2 cytokine imbalance in meningioma, anaplastic astrocytoma and glioblastoma multiforme patients. Oncol Rep, 2006. 15(6): p. 1513-6.
  40. Hanada, T. and A. Yoshimura, Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev, 2002. 13(4-5): p. 413-21.
  41. Stewart-Akers, A.M., et al., Effect of granulocyte-macrophage colony-stimulating factor on lymphokine-activated killer cell induction. Blood, 1993. 81(10): p. 2671-8.
  42. Koff, W.C., et al., Efficient activation of human blood monocytes to a tumoricidal state by liposomes containing human recombinant gamma interferon. Cancer Immunol Immunother, 1985. 19(2): p. 85-9.
  43. Ferrante, A., Activation of neutrophils by interleukins-1 and -2 and tumor necrosis factors. Immunol Ser, 1992. 57: p. 417-36.
  44. Sarzotti, M., G.R. Klimpel, and S. Baron, Long-term killing of natural killer-resistant target cells by interferon-alpha-, interferon-gamma-, and interleukin-2-activated natural killer cells. Nat Immun Cell Growth Regul, 1989. 8(2): p. 66-75.
  45. Kamamura, Y., et al., Effects of interferon-alpha and gamma on development of LAK activity from mononuclear cells in breast cancer patients. J Med Invest, 1998. 45(1-4): p. 71-5.
  46. Zitvogel, L., et al., Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med, 1996. 183(1): p. 87-97.
  47. Barth, R.J., Jr., et al., Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med, 1991. 173(3): p. 647-58.
  48. Vermorken, J.B., et al., Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet, 1999. 353(9150): p. 345-50.
  49. O'Donnell, M.A., et al., Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guerin. J Immunol, 1999. 163(8): p. 4246-52.
  50. Schirrmacher, V. and C. Haas, Modification of cancer vaccines by virus infection and attachment of bispecific antibodies. An effective alternative to somatic gene therapy. Adv Exp Med Biol, 1998. 451: p. 251-7.
  51. Chan, A.D. and D.L. Morton, Active immunotherapy with allogeneic tumor cell vaccines: present status. Semin Oncol, 1998. 25(6): p. 611-22.
  52. Nastala, C.L., et al., Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol, 1994. 153(4): p. 1697-706.
  53. Brunda, M.J., et al., Role of interferon-gamma in mediating the antitumor efficacy of interleukin-12. J Immunother Emphasis Tumor Immunol, 1995. 17(2): p. 71-7.
  54. Street, S.E., E. Cretney, and M.J. Smyth, Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood, 2001. 97(1): p. 192-7.
  55. Smyth, M.J., M. Taniguchi, and S.E. Street, The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J Immunol, 2000. 165(5): p. 2665-70.
  56. Asher, A.L., et al., Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors. J Immunol, 1991. 146(9): p. 3227-34.
  57. Asher, A.L., J.J. Mule, and S.A. Rosenberg, Recombinant human tumor necrosis factor mediates regression of a murine sarcoma in vivo via Lyt-2+ cells. Cancer Immunol Immunother, 1989. 28(2): p. 153-6.
  58. Gruss, H.J., Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily. Int J Clin Lab Res, 1996. 26(3): p. 143-59.
  59. Wallach, D., et al., Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol, 1999. 17: p. 331-67.
  60. Koshiji, M., et al., Apoptosis of colorectal adenocarcinoma (COLO 201) by tumour necrosis factor-alpha (TNF-alpha) and/or interferon-gamma (IFN-gamma), resulting from down-modulation of Bcl-2 expression. Clin Exp Immunol, 1998. 111(1): p. 211-8.
  61. Spets, H., et al., Fas/APO-1 (CD95)-mediated apoptosis is activated by interferon-gamma and interferon- in interleukin-6 (IL-6)-dependent and IL-6-independent multiple myeloma cell lines. Blood, 1998. 92(8): p. 2914-23.
  62. Eksioglu, E.A., et al., GM-CSF promotes differentiation of human dendritic cells and T lymphocytes toward a predominantly type 1 proinflammatory response. Exp Hematol, 2007.
  63. Suh, K.W., et al., Treatment of liver metastases from colon carcinoma with autologous tumor vaccine expressing granulocyte-macrophage colony-stimulating factor. J Surg Oncol, 1999. 72(4): p. 218-24.
  64. Gately, M.K., et al., Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell Immunol, 1992. 143(1): p. 127-42.
  65. Trinchieri, G., Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood, 1994. 84(12): p. 4008-27.
  66. Hayes, M.P., J. Wang, and M.A. Norcross, Regulation of interleukin-12 expression in human monocytes: selective priming by interferon-gamma of lipopolysaccharide-inducible p35 and p40 genes. Blood, 1995. 86(2): p. 646-50.
  67. Manetti, R., et al., Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med, 1993. 177(4): p. 1199-204.
  68. Trinchieri, G., Interleukin-12 and its role in the generation of TH1 cells. Immunol Today, 1993. 14(7): p. 335-8.
  69. He, X.Z., L. Wang, and Y.Y. Zhang, An effective vaccine against colon cancer in mice: use of recombinant adenovirus interleukin-12 transduced dendritic cells. World J Gastroenterol, 2008. 14(4): p. 532-40.

Clinical Trial of an Experimental
Cancer Vaccine
  • Personalized experimental anti cancer vaccine
  • Combines tumor cryoablation with AlloStim™

CryoStim™ Animation

Have Questions?

Chat Now
Specialist Available